New York City Public Schools students can obtain work experience in health care through a partnership with Memorial Sloan ...

Researchers at Mount Sinai and Memorial Sloan Kettering believe they’ve made a breakthrough in a new form of cancer treatment ...

Eligibility for treatment with the latest cancer drugs is often determined by genetic mutations in tumors, criteria that ...

Patients of European ancestry are more likely to find a match to the latest targeted cancer drugs than patients of other ...

A collaborative effort between Mount Sinai and Memorial Sloan Kettering Cancer Center has shed valuable light on how ...

Researchers at The Tisch Cancer Institute at Mount Sinai, in collaboration with Memorial Sloan Kettering Cancer Center (MSK), ...

Research suggests the benefits of testosterone therapy after prostate cancer surgery in select men may outweigh risks.

The age of testing for colorectal cancer has been pushed from 50 to 45, and it is even earlier for at-risk patients because of the rise in the number of young adults being diagnosed with the disease.

Testing BRCA2 has long been a staple of hereditary cancer testing, as pathogenic variants in the gene are associated with cancers of the breast, ovary, prostate, and pancreas. 2-5 Despite the ...

Determining which cancer patients are a good candidate for immune checkpoint inhibitors can be a challenge, but researchers at Mount Sinai and Memorial Sloan Kettering Cancer Center have developed a ...

Oncologist David Chung is taking on Northwell Health's newly established role of director of clinical research at its cancer ...